Latest news articles

Added 5 years ago Drug news

FDA approves updated Surfaxin (Discovery Labs) for RDS

The FDA has agreed to Discovery Lab's updated product specifications for Surfaxin (lucinactant) Intratracheal Suspension which was approved in 2012...

Added 7 years ago Drug news

Surfaxin (Discovery Labs) is FDA approved for Respiratory Distress Syndrome

The FDA has approved Surfaxin (lucinactant) from Discovery Laboratories for the prevention of Respiratory Distress Syndrome (RDS), a breathing disorder...

Added 7 years ago Drug news

Surfaxin is re-filed at FDA for Respiratory Distress Syndrome

The FDA has accepted the re-application for the humanised surfactant Surfaxin (lucinactant) from Discovery Laboratories as a preventive therapy for...

Search all news articles for Respiratory distress syndrome of newborn
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Guidelines

Specialist neonatal respiratory care for babies born preterm

This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.

Added 1 month ago

Search all guidelines for Respiratory distress syndrome of newborn